Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024年7月3日 - 5:01AM
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage
biopharmaceutical company dedicated to bringing a first-in-class
pipeline of induced pluripotent stem cell (iPSC)-derived cellular
immunotherapies to patients with cancer and autoimmune diseases,
today announced that on July 1, 2024 the Company granted restricted
stock units (RSUs) representing 28,200 shares of its common stock
to three newly-hired non-executive employees. The grants were
approved by the Compensation Committee of the Company’s Board of
Directors and granted under the Company’s Amended and Restated
Inducement Equity Plan as an inducement material to the new
employees entering into employment with the Company in accordance
with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four
years, with 25% of the shares underlying each RSU award vesting on
each anniversary of the grant date, subject to the employee being
continuously employed by the Company through each vesting date.
About Fate Therapeutics’ iPSC Product
PlatformThe Company’s proprietary induced pluripotent stem
cell (iPSC) product platform enables mass production of
off-the-shelf, multiplexed-engineered cell products that are
selectively designed, incorporate novel synthetic controls of cell
function, and are intended to deliver multiple mechanisms of
therapeutic importance to patients. Human iPSCs possess the unique
dual properties of unlimited self-renewal and differentiation
potential into all cell types of the body. The Company’s platform
combines multiplexed engineering and single-cell selection of human
iPSCs to create clonal master iPSC lines. Analogous to master cell
lines used to mass produce biopharmaceutical drug products such as
monoclonal antibodies, the Company utilizes its clonal master iPSC
lines as a renewable cell source to manufacture
multiplexed-engineered cell products which are well-defined and
uniform in composition, can be stored in inventory for
off-the-shelf availability, can be combined and administered with
other therapies, and can potentially reach a broad patient
population. As a result, the Company’s platform is uniquely
designed to overcome numerous limitations associated with the
manufacture of cell therapies using patient- or donor-sourced
cells. Fate Therapeutics’ iPSC product platform is supported by an
intellectual property portfolio of over 400 issued patents and 450
pending patent applications.
About Fate Therapeutics,
Inc.Fate Therapeutics is a clinical-stage
biopharmaceutical company dedicated to bringing a first-in-class
pipeline of induced pluripotent stem cell (iPSC)-derived cellular
immunotherapies to patients with cancer and autoimmune diseases.
Using its proprietary iPSC product platform, the Company has
established a leadership position in creating
multiplexed-engineered iPSC lines and in the manufacture and
clinical development of off-the-shelf, iPSC-derived cell products.
The Company’s pipeline includes iPSC-derived natural killer (NK)
cell and T-cell product candidates, which are selectively designed,
incorporate novel synthetic controls of cell function, and are
intended to deliver multiple therapeutic mechanisms to patients.
Fate Therapeutics is headquartered in San Diego, CA. For more
information, please visit www.fatetherapeutics.com.
Contact:Christina
TartagliaPrecision
AQ212.362.1200christina.tartaglia@precisionaq.com
Fate Therapeutics (NASDAQ:FATE)
過去 株価チャート
から 6 2024 まで 7 2024
Fate Therapeutics (NASDAQ:FATE)
過去 株価チャート
から 7 2023 まで 7 2024